CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 5, 2020–
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company, along with its academic collaborators, will present four abstracts, including three oral and one poster presentation, and participate in two pre-meeting programs, at the 23rd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), which will be held virtually May 12-15, 2020. The oral presentations will include data updates for its investigational programs for Fabry disease and cystinosis, as well as preclinical data for its investigational program for Pompe disease.
Details on oral presentations:
Hematopoietic stem cell gene therapy for cystinosis: initial results from a Phase I/II clinical trial
- Stephanie Cherqui, Ph.D., principal investigator of the Phase 1/2